IO Biotech Statistics
Share Statistics
IO Biotech has 65.88M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 65.88M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 44.81M |
| Failed to Deliver (FTD) Shares | 4.46K |
| FTD / Avg. Volume | 1.19% |
Short Selling Information
The latest short interest is 200.92K, so 0.3% of the outstanding shares have been sold short.
| Short Interest | 200.92K |
| Short % of Shares Out | 0.3% |
| Short % of Float | 0.45% |
| Short Ratio (days to cover) | 1.89 |
Valuation Ratios
The PE ratio is -0.95 and the forward PE ratio is -0.79.
| PE Ratio | -0.95 |
| Forward PE | -0.79 |
| PS Ratio | 0 |
| Forward PS | 2 |
| PB Ratio | 0.61 |
| P/FCF Ratio | -1.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for IO Biotech Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.37, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.37 |
| Quick Ratio | 9.37 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.84 |
| Cash Flow / Debt | -28.76 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.65% and return on capital (ROIC) is -68.08%.
| Return on Equity (ROE) | -0.65% |
| Return on Assets (ROA) | -0.57% |
| Return on Capital (ROIC) | -68.08% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.16M |
| Employee Count | 74 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 852.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -56.11% in the last 52 weeks. The beta is 0.42, so IO Biotech 's price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | -56.11% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 1.2 |
| Relative Strength Index (RSI) | 38.62 |
| Average Volume (20 Days) | 375.85K |
Income Statement
| Revenue | n/a |
| Gross Profit | -756.00K |
| Operating Income | -91.44M |
| Net Income | -86.08M |
| EBITDA | -91.23M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.98 |
Balance Sheet
The company has 143.19M in cash and 2.49M in debt, giving a net cash position of 140.70M.
| Cash & Cash Equivalents | 143.19M |
| Total Debt | 2.49M |
| Net Cash | 140.70M |
| Retained Earnings | -263.82M |
| Total Assets | 89.94M |
| Working Capital | 70.19M |
Cash Flow
In the last 12 months, operating cash flow was -71.74M and capital expenditures -323.00K, giving a free cash flow of -72.06M.
| Operating Cash Flow | -71.74M |
| Capital Expenditures | -323.00K |
| Free Cash Flow | -72.06M |
| FCF Per Share | -1.66 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IOBT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -250.63% |
| FCF Yield | -138.47% |
Analyst Forecast
The average price target for IOBT is $10, which is 1165.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 1165.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -5.72 |
| Piotroski F-Score | 2 |